Text Size

Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis

This study has been completed.
Sponsor:
Information provided by:
Centocor, Inc.
ClinicalTrials.gov Identifier:
NCT00269867
First received: December 22, 2005
Last updated: April 23, 2010
Last verified: April 2010
History of Changes
  Purpose

The purpose of this study is to evaluate the safety and effectiveness of infliximab (an anti-TNF chimeric monoclonal antibody [cA2]) in patients with active Rheumatoid Arthritis, despite methotrexate treatment.


Condition Intervention Phase
Rheumatoid Arthritis
 Drug: Infliximab
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Placebo-Controlled, Double-Blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Centocor, Inc.:

Primary Outcome Measures:
  • Change from baseline in ACR20 response at week 30; Change in modified van der Heijde-Sharp Score

Secondary Outcome Measures:
  • safety

Estimated Enrollment: 428
Detailed Description:

This is a placebo-controlled, double-blinded, randomized clinical study to evaluate the safety and effectiveness of infliximab in patients with active Rheumatoid Arthritis, despite methotrexate treatment. Infliximab is an anti-TNF chimeric monoclonal antibody (cA2). The primary measures of effectiveness include the change from baseline in American College of Rheumatology (ACR20) response at week 30, and the change in the modified van der Heijde Sharp Score. The ACR20 Responder Index a composite of clinical, laboratory, and functional measures and the van der Heijde-Sharp (vdH-S) scoring method is a method of rating structural damage in patients..

Patients will be treated with either infliximab or matching placebo.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with active Rheumatoid Arthritis despite treatment with methotrexate
  • Diagnosed with Rheumatoid Arthritis at least 6 months prior to screening
  • Having active disease at the time of screening and pre-infusion as defined by having at least 6 or more swollen joints and 6 or more tender joints
  • Using methotrexate for at least 3 months prior to study enrollment

Exclusion Criteria:

  • Patients having any systemic inflammatory condition
  • Having Lyme disease or a rheumatic disease other than Rheumatoid Arthritis
  • Who have used Disease-Modifying Antirheumatic Drugs (DMARDs) other than methotrexate within 4 weeks prior to screening
  • Who have used corticosteroids within 4 weeks prior to screening
  • Having received previous administration of infliximab
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00269867

Sponsors and Collaborators
Centocor, Inc.
Investigators
Study Director: Centocor, Inc. Clinical Trial Centocor, Inc.
  More Information

Publications:

ClinicalTrials.gov Identifier: NCT00269867     History of Changes
Other Study ID Numbers: CR006259
Study First Received: December 22, 2005
Last Updated: April 23, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Centocor, Inc.:
Rheumatoid Arthritis
infliximab
methotrexate

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Methotrexate
Infliximab
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
 Therapeutic Uses
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors
Gastrointestinal Agents
Anti-Inflammatory Agents

ClinicalTrials.gov processed this record on May 19, 2013